March 2021 Fusion - Next Generation TATs for Precision Oncology Targeted Alpha Therapies (TATs) deliver radiation directly to cancer cells using a precision medicine approach (theranostics) ■ Fusion can create TATs from wide range of targeting molecules (antibodies, proteins, small molecules) We are expanding our pipeline by acquiring a small molecule that binds NTSR1; a validated cancer marker found on multiple cancer types notably pancreatic and colorectal cancers ■ Clinical imaging data show uptake of diagnostic form in pancreatic and CRC cancer patients ■ Preclinical therapy data with 225Ac (alpha emitter) show single dose tumor kill - high potency This first in class radiopharmaceutical augments our programs: